In vitro evaluation of antibiotic lock technique for the treatment of candida albicans, C. glabrata, and C. tropicalis biofilms

Journal of Korean Medical Science

Volumn 25, Issue 12, 2010, Pages 1722-1726

  Ko, Kwan Soo ^a,b   Lee, Ji Young ^a   Song, Jae Hoon ^a,b   Peck, Kyong Ran ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Asia Pacific Foundation for Infectious Diseases (APFID)   (South Korea)

Author keywords

Antibiotic lock technique; Biofilms; Candida

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; CATHETER INFECTION; CENTRAL VENOUS CATHETERIZATION; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; EVALUATION; HUMAN; MICROBIOLOGICAL EXAMINATION; PHYSIOLOGY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; DRUG ADMINISTRATION ROUTES; ECHINOCANDINS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 78649924555     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.12.1722     Document Type: Article

References (21)

1. Han SS, Yim JJ, Yoo CG, Kim YW, Han SK, Shim YS, Lee SM. Clinical characteristics and risk factors for nosocomial candidemia in medical intensive care units: experience in a single hospital in Korea for 6.6 years. J Korean Med Sci 2010; 25: 671-6.
2. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
3. Mukherjee PK, Long L, Kim HG, Ghannoum MA. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int J Antimicrob Agents 2009; 33: 149-53.
4. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51: 1-29.
5. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008; 62: 153-5.
6. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, López-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against performed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46: 3634-6.
7. Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 2006; 194: 710-3.
8. Lee JY, Ko KS, Peck KR, Oh WS, Song JH. In vitro evaluation of the anti biotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob Chemother 2006; 57: 1110-5.
9. Lee MY, Ko KS, Song JH, Peck KR. In vitro effectiveness of the antibiotic lock technique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae. J Antimicrob Chemother 2007; 60: 782-7.
10. Donlan RM. Biofilms on central venous catheters: is eradication possible? Curr Top Microbiol Immunol 2008; 322: 133-61.
11. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute 2008; Document No. M27-A2.
12. Hawser SP, Norris H, Jessup CJ, Ghannoum MA. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]- 2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol 1998; 36: 1450-2.
13. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
14. Golomb G, Shpigelman A. Prevention of bacterial colonization on polyurethane in vitro by incorporated antibacterial agent. J Biomed Mater Res 1991; 25: 937-52.
15. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081-8.
16. Raad II, Hanna HA. Intravascular catheter-related infections: new horizons and recent advances. Arch Intern Med 2002; 162: 871-8.
17. Schinabeck MK, Long LA, Hossain MA, Chandra J, Mukherjee PK, Mohamed S, Ghannoum MA. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother 2004; 48: 1727-32.
18. Buckler BS, Sams RN, Goei VL, Krishnan KR, Bemis MJ, Parker DP, Murray DL. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy. Pediatr Infect Dis J 2008; 27: 762-4.
19. Bachmann SP, Ramage G, VandeWalle K , Patterson TF, Wickes BL, López-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother 2003; 47: 3657-9.
20. Ferreira JA, Carr JH, Starling CE, De Resende MA, Donlan RM. Biofilm formation and the effect of caspofungin on the biofilm structure of Candida species bloodstream isolates. Antimicrob Agents Chemother 2009; 53: 4377-84.
21. Perumal P, Mekala S, Chaffin WL. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother 2007; 51: 2454-63.